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Therapeutic delivery of hydrogen sulfide for
salvage of ischemic skeletal muscle after the onset
of critical ischemia
Peter W. Henderson, MD, Natalia Jimenez, BA, John Ruffino, BA, Allie M. Sohn, BS,
Andrew L. Weinstein, BS, David D. Krijgh, BA, Alyssa J. Reiffel, MD, and Jason A. Spector, MD,
New York, NY
Background: Recent evidence suggests that hydrogen sulfide is capable of mitigating the degree of cellular damage
associated with ischemia-reperfusion injury (IRI).
Methods:This study evaluated the potential utility of hydrogen sulfide in preventing IRI in skeletal muscle by using in vitro
(cultured myotubes subjected to sequential hypoxia and normoxia) and in vivo (mouse hind limb ischemia, followed by
reperfusion) models to determine whether intravenous hydrogen sulfide delivered after the ischemic event had occurred
(pharmacologic postconditioning) conferred protection against IRI. Injury score and apoptotic index were determined by
analysis of specimens stained with hematoxylin and eosin and terminal deoxynucleotide transferase-mediated deoxy-
uridine triphosphate nick-end labeling, respectively.
Results: In vitro, hydrogen sulfide reduced the apoptotic index after 1, 3, or 5 hours of hypoxia by as much as 75% (P 
.002), 80% (P  .006), and 83% (P < .001), respectively. In vivo, hydrogen sulfide delivered after the onset of hind limb
ischemia and before reperfusion resulted in protection against IRI-induced cellular changes, which was validated by
significant decreases in the injury score and apoptotic index. The timing of hydrogen sulfide delivery was crucial: when
delivered 20 minutes before reperfusion, hydrogen sulfide conferred significant cytoprotection (P< .001), but treatment
1 minute before reperfusion did not provide protection (P  NS).
Conclusions: These findings confirm that hydrogen sulfide limits IRI-induced cellular damage in myotubes and skeletal
muscle, even when delivered after the onset of ischemia in this murine model. These data suggest that when given in the
appropriate dose and within the proper time frame, hydrogen sulfide may have significant therapeutic applications in
multiple clinical scenarios. ( J Vasc Surg 2011;53:785-91.)
Clinical Relevance: Extremity ischemia is a limb- and life-threatening clinical scenario that must be treated expeditiously.
Although rapid recognition and revascularization is crucial, there are few options regarding pharmacologic means to
mitigate the effect of ischemia and subsequent reperfusion (ischemia-reperfusion injury). This is particularly true in
situations of unanticipated ischemia, where no interventions can be undertaken before the onset of ischemia. Hydrogen
sulfide is protective of muscle cells against ischemia-reperfusion injury when delivered before the onset of ischemia, and
this study evaluated the effect of hydrogen sulfide delivered after the onset of ischemia. The promising results of the in
vitro and in vivo studies suggest that hydrogen sulfide may in the future be an important adjunct to prompt surgical or
endovascular intervention in episodes of unanticipated extremity ischemia.
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pAcute vascular occlusion of the lower extremity can
result from embolism, thrombosis, or extrinsic compres-
sion. Because of the relatively high metabolic rate of even
resting muscle tissue, an ischemic interval as short as 2
From the Laboratory for Bioregenerative Medicine and Surgery, Depart-
ment of Surgery, Weill Cornell Medical College.
This project was funded by grants from the Plastic Surgery Education
Foundation (BRG 09-07), the New York State Empire Clinical Research
Investigator Program (ECRIP), and the Weill Cornell Medical College
Clinical and Translational Science Center (TL1RR024998).
Competition of interest: none.
Presented in part at the Twenty-third Annual Meeting of the Eastern Vascular
Society, Philadelphia, Pa, Sep 24, 2009; and at the American College of
Surgeons Clinical Congress, Chicago, Ill, Oct 13, 2009.
Reprint requests: Jason A. Spector, MD, 525 E 68th St, Payson 709A, New
York, NY 10065 (e-mail: jas2037@med.cornell.edu); http://www.
bioregenerativetechnologies.com).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00
Copyright © 2011 Published by Elsevier Inc. on behalf of the Society ford
Vascular Surgery.
doi:10.1016/j.jvs.2010.10.094oursmay begin to produce severe and irreversible injury to
yocytes. This is likely caused by the initial stress of the
schemia, which is further exacerbated by the generation of
arge quantities of reactive oxygen species upon reperfusion
nd exposure of the ischemic tissue to oxygen-containing
lood.
The damage caused upon revascularization of acutely
schemic tissue, known as ischemia-reperfusion injury
IRI), ranges from edema to frank necrosis, depending
pon the length of the ischemic interval and the tissue(s)
nvolved. In the lower extremity, obligatory swelling
aused by reperfusion may result in further ischemia be-
ause of the limited compliance of the thick fascial compart-
ents of the lower leg. To prevent further compromise of
he neural and muscle tissues within the compartments,
asciotomies must be performed, often leading to immobi-
ization, skin grafting, and other morbidity due to the
rolonged recovery period.
For scenarios of planned ischemia, such as organ trans-
lantation and free tissue transfer, strategies have been
evised to protect tissue from the sequelae of IRI. Theo-
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March 2011786 Henderson et alretically, a cytoprotective agent delivered before the onset
of ischemia could ameliorate the consequences of IRI.
Toward that end, several compounds have been evaluated,
with varying degrees of success.1-3
In the clinical setting, however, the onset of acute
ischemia is often unanticipated, whichmakes the delivery of
a protective agent before the onset of ischemia impossible.
Thus, for a compound to be efficacious, it must provide
protection when given after the onset of ischemia.
Hydrogen sulfide (HS) has historically been thought of
as an environmental toxic gas,4-6 but it is now known to be
an endogenous signaling molecule7-11 in the gasotransmit-
ter family, along with nitric oxide and carbon monox-
ide.12-14 This molecule provides significant protection in
cardiac, neurologic, and hepatic models of IRI when deliv-
ered before an ischemic insult.15-22
Our laboratory recently demonstrated that pharmaco-
logic preconditioning with HS confers significant long-
term protection against IRI in skeletal muscle for ischemic
intervals lasting up to 3 hours.23 The potential cytoprotec-
tive effect of HS in skeletal muscle when delivered after the
onset of ischemia, however, has not yet been broadly eval-
uated. Furthermore, none of the previous studies fully
examined the relationship between the timing of HS deliv-
ery and its protective efficacy. Therefore, the purpose of this
study was to determine whether pharmacologic postcondi-
tioning with HS is efficacious in reducing IRI in skeletal
muscle.
METHODS
HS donor modalities. For in vitro as well as in vivo
studies, the HS donor was NaHS (Alfa Aesar, Ward Hill,
Mass) dissolved in sterile phosphate buffered saline (PBS;
EMD Chemicals; Gibbstown, NJ), with a final pH of 8.5.
In vitro myotube anoxia-normoxia studies. Murine
myoblasts (ATCC, Manassas, Va) were grown in culture at
37°C in Dulbecco’s Modified Eagle’s Media (Mediatech,
Manassas, Va) that had been supplemented with 10% fetal
bovine serum (JR Scientific, Woodland, Calif) and 1%
penicillin/streptomycin (Mediatech) until the cells became
80% confluent. Myoblasts were then were plated into
8-well chamber slides (Nunc, Rochester, NY) at a density of
1  104 cells/well and subsequently differentiated into
myotubes upon exposure to media containing 2% horse
serum (PMLMicrobiologicals, Wilsonville, Ore) in place of
the fetal bovine serum. All studies were performed on
passage 4 cells, 4 days after exposure to horse serum.
The cells were exposed to 1, 3, or 5 hours of hypoxia
(1% oxygen) in a dual-chamber hypoxia chamber. Cells
were treated 20 minutes before the ends of the hypoxic
period with the same horse serum-containing media, mod-
ified by the addition of equal volumes of varying concen-
trations of NaHS to bring the final HS concentration in the
media to 0, 0.1, 1.0, 10, 100, and 1000 M. The pH of
the media (8.5) did not change with addition of NaHS. At
the end of the hypoxic period, the cells were returned to a
standard incubator for 3 hours of normoxia (21% oxygen).
A separate sample of myotubes plated in the same manner cnd treated with the same amount of NaHS-containing
edia was kept at 21% oxygen as a normoxic control.
yotubes were then fixed in 4% para-formaldehyde (Alfa
esar) for 1 hour and stored at 20°C. All experiments
ere repeated in triplicate.
Assay to assess apoptosis. The terminal deoxynucle-
tide transferase-mediated deoxyuridine triphosphate nick-
nd labeling (TUNEL) assay was used to assess the degree
f apoptosis. The in situ cell death detection kit (Roche
pplied Science, Indianapolis, Ind) with Prolong Gold
ntifade reagent and 4=,6-diamidino-2-phenylindole
DAPI) counterstain (Invitrogen, Carlsbad, Calif) were
sed per the manufacturers’ instructions. Briefly, slides
ere rinsed in PBS for 5 minutes and permeabilized with
.1% Triton X-100 (MP Biomedicals, Solon, Ohio) and
.1% citric acid (Mallinckrodt, Hazelwood, Mo). The
UNEL solution was applied to all slides for 1 hour, and
hen the counterstain was applied and allowed to develop
vernight.
Determination of apoptotic index. TUNEL-stained
yotubes were analyzed using florescent microscopy. The
poptotic index (AI) was determined by quantifying the
verage number of TUNEL-positive myocyte nuclei di-
ided by the number of TUNEL-negative/DAPI-positive
yocyte nuclei across five random high-powered fields
original magnification, 200) by two blinded observers.
luorescent microscopy was performed with a Nikon e800
pright microscope with DAPI/fluorescein isothiocyanate
lter (Nikon, Tokyo, Japan). Values are presented as mean
tandard error of the mean.
In vivo mice studies. All in vivo studies used 8-week-
ld male C57Bl/6 mice (Jackson Laboratory, Bar Harbor,
e). All animal care and experimental procedures were in
ompliance with the Guide for the Care and Use of Labo-
atory Animals24 and were approved by the Weill Cornell
edical College Institutional Animal Care and Use Com-
ittee (IACUC # 0704-607A).
Murine hind limb ischemia-reperfusion studies.
ighteen mice were anesthetized by an intraperitoneal in-
ection of ketamine (80 mg/kg) and xylazine (60 mg/kg).
ind limb ischemia was performed as previously de-
cribed.23 Briefly, a tourniquet was applied around the hind
imb, superior to the greater trochanter, thereby occluding
ll blood flow to distal tissue. The contralateral leg served as
nonischemic control. Either 1 or 20 minutes before the
nd of the ischemic period, mice received a tail vein injec-
ion of 200 L PBS containing 0 or 0.98 g NaHS. Based
n the estimated circulating blood volume (7% of 25 g, or
.75 mL), this amount of NaHS raised the final blood-
tream concentration to 10 M (n 6 for each group). Fig
summarizes the timeline for HS delivery for all experi-
ents.
After 3 hours of ischemia, the tourniquet was removed
nd the ischemic limb was allowed to reperfuse for 3 hours
reperfusion was confirmed by the rapid onset of hyperemia
f the limb). At that time, the mice were euthanized by
arbon dioxide asphyxiation and cervical dislocation ac-
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Volume 53, Number 3 Henderson et al 787cording to institutional protocol, and the gastrocnemius
muscle was harvested and processed.
Tissue processing. Excised muscle was washed in PBS
and dissected free of excess fat and fascia and fixed in 10%
buffered formalin for 24 hours, dehydrated, then embed-
ded in paraffin. Ten-micrometer sections of all samples
were stained with hematoxylin and eosin (H&E) or
TUNEL (staining and apoptotic index calculation were
performed as described above).25
Determination of injury score. The injury score (IS)
was determined by a protocol based on that which has been
established by McCormack et al.26 Four random photomi-
crographs were taken of each H&E-stained section, and
based on the proportion of injured cells (defined by ragged
cellular borders, vacuolization, lymphocytic infiltration, or
rhabdomyolysis), blinded reviewers assigned a numerical
value between 0 and 10 for each in vivo experiment. Values
are presented as mean  standard error of the mean.
Statistical analysis. Statistical significance was deter-
mined by first performing a square root transformation to
the data to correct for heteroscedasticity (differing vari-
ances). Subsequently, a series of independent measures
t-tests with a family error rate of   0.05 was performed.
RESULTS
In vitro study. In myotubes subjected to 1 hour of
hypoxia, followed by 3 hours of normoxia, non-HS-treated
cells had a mean AI of 5.7% 1.0%, cells treated with 1 M
HS had a mean AI of 2.6% 0.3% (P .013), cells treated
with 10 MHS had a mean AI of 1.0% 0.3% (P .002),
Fig 1. Summary of time of NaHS delivery (arrow) for the pre-
ischemic, preischemic (long-term), postischemic (1minutes before
reperfusion), and postischemic (20 minutes before reperfusion)
experimental groups.and cells treated with 100 M had a mean AI of 1.4%  r.5% (P  .006; Fig 2). In myotubes subjected to 3 hours
f hypoxia, followed by 3 hours of normoxia, non-HS-
reated cells had a mean AI of 8.4%  2.2%, cells treated
ith 1 MHS had a mean AI of 2.1%  0.7% (P  .016),
ells treated with 10 MHS had a mean AI of 1.7% 0.3%
P .006), and cells treated with 100Mhad amean AI of
.4%  0.5% (P  NS). In myotubes subjected to 5 hours
f hypoxia, followed by 3 hours of normoxia, non-HS-
reated cells had a mean AI of 8.9%  1.0%, cells treated
ith 1 MHS had a mean AI of 1.5%  0.3% (P  .001),
ells treated with 10 MHS had a mean AI of 1.7% 0.4%
P .001), and cells treated with 100Mhad amean AI of
.0%  0.3% (P  .001).
In HS-treated normoxic cells, no difference in the rate
f apoptosis compared with control (non-HS treated, nor-
oxic) was noted at any of the tested doses (data not
hown).
In vivo studies. In vivo studies in which NaHS was
elivered after the induction of ischemia, but before reper-
usion, demonstrated a relative preservation of normal mus-
le architecture with minimal extracellular edema when
elivered 20 minutes before reperfusion. In contrast, this
rotection was not observed when NaHS was delivered
nly 1 minute before reperfusion, which resulted in signif-
cant membranous discontinuity, extracellular edema, and
ntracellular vacuolization (Fig 3). The IS was 3.4 0.8 for
uscle from non-NaHS-treated mice, 2.1 0.2 (P NS)
or those treated with 10 M NaHS 1 minute before
eperfusion, and 0.5  0.1 (P  .001) for those treated
ith 10 M NaHS 20 minutes before reperfusion. The
UNEL assay showed that at the 10 M dose, the AI was
educed by 84% (P  .001) when delivered 20 minutes
efore reperfusion and was reduced by only 29% (P  NS)
hen delivered 1 minute before reperfusion (Fig 4).
ISCUSSION
Unanticipated acute ischemia remains a challenging clin-
cal problem. In tissues with a high metabolic demand, irre-
ersible damage may occur when perfusion is re-established
fter even brief ischemic intervals, the result of an abun-
ance of reactive oxygen species generated from the sudden
nflux of oxygen-bearing blood. Because of the relatively
igh metabolic rate of skeletal muscle (even at rest), the
indow for successful revascularization of the acutely isch-
mic lower extremity remains brief.
Even when revascularization occurs in a relatively
imely fashion, subsequent IRI often results in cellular and
issue edema that may necessitate further morbid interven-
ions such as fasciotomy. When profound ischemia lasts2
ours, irreversible damage occurs to muscle and nerve
issue within the affected limb. In the short term, myone-
rosis may lead to myoglobinuria and renal failure. Longer-
erm sequelae include fibrosis and contracture of the af-
ected muscle, which in combination with ischemic nerve
amage results in permanent and critical disability. In more
evere cases, gangrene and subsequent amputation may
esult.
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efficacy of pharmacologic preconditioning with HS in
preventing the untoward effects of IRI in skeletal mus-
cle.23,27-30 HS is thought to be produced in most tissues
throughout the body from L-cysteine, primarily by the en-
zymes cystathionine-	-synthase (CBS) and cystathionine-
	-lyase (CSE). Multiple tissues types contain both of these
enzymes, but CBS is thought to predominate in the central
nervous system, and CSE predominates in the cardiovascu-
lar system.31 HS is now known to have protean effects,
including the regulation of inflammation and vascular per-
meability, vasomotor tone, and cellular metabolism among
Fig 2. Myotube apoptotic index measured after 1, 3, and
star denotes statistical significance compared with non-N
repeated in triplicate. The stars indicate P  .05 relative
Fig 3. Photomicrographs show muscle after postischem
magnification,100). A, Injury score nonischemic contr
treated with NaHS, (C) ischemic-reperfused tissue that ha
and (D) ischemic-reperfused tissue that had been treated
preservation of normal muscle architecture after treatme
preservation when delivered only 1 minute before reperfusimany others. fThe mechanism through which HS confers protection
gainst IRI remains largely unknown, but it is thought to
e multifactorial (Fig 5). In addition to functioning as a
irect scavenger of reactive oxygen species, HS appears to
pen mitochondrial KATP channels, which prevents mito-
hondrial hyperpolarization, calcium overload, and fatal
pening of the mitochondrial permeability transition
ore.11,20 In addition, HS may activate prosurvival signal-
ng cascades such as the reperfusion injury salvage kinases
RISK), which include PI3-kinase/Akt and extracellular
ignal-regulated kinase, among others.32 Furthermore, the
ecrease in metabolism that results from HS may provide
urs of hypoxia, all followed by 3 hours of normoxia. The
reated control for each respective time. All cultures were
n-NaHS-treated cells at each time.
elivery of NaHS (n  6 for each study group; original
scle, (B) ischemic-reperfused muscle that had not been
n treated with 10 MNaHS 1 minute before reperfusion,
10 M NaHS 20 minutes before reperfusion. Note the
ith NaHS 20 minutes before reperfusion but minimal5 ho
aHS-tic d
ol mu
d bee
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nt wurther protection from the ischemic interval by directly
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species upon reperfusion. This last mechanism, however,
would not appear to be relevant to protection conferred by
postconditioning.
In our previous studies, HS delivered 20 minutes be-
fore the onset of 3 hours of ischemia, followed by 3 hours of
reperfusion, abolished evidence of IRI.21,23 Our data also
indicated that optimal protection was conferred when ex-
ogenously delivered HS increased the intravascular HS
concentration to 10 M. Although pretreatment of tissues
with HS would certainly provide benefits in clinical scenar-
ios of anticipated ischemia, as noted above, acute lower
extremity ischemia in the clinical setting is usually impossi-
ble to anticipate. Therefore, based on the promising results
from our studies evaluating the “preischemic” delivery of
HS, we sought to determine whether HS could provide
protection even when delivered after the onset of ischemia
and therefore not reach the target tissue until after reper-
fusion.
As our data demonstrate, pharmacologic postcondi-
tioning with NaHS delivered after the onset of 1, 3, or 5
hours of hypoxia is capable of protecting cells against
simulated IRI in vitro. Furthermore, when HS is delivered
in vivo after 3 hours of ischemia but before reperfusion,
similar protection was conferred to skeletal muscle. More
important, the ischemic intervals used in these studies
extended well beyond the established clinical limit of 2
hours of ischemia, after which point irreversible damage
begins to occur in muscle tissue.33 This is significant be-
cause in the clinical arena, all cases of unanticipated tissue
ischemia and even most scenarios of anticipated tissue
Fig 4. Muscle after postischemic delivery of NaHS (n  6 for
each study group). Apoptotic index for nonischemic control mus-
cle, ischemic-reperfused muscle that had not been treated with
NaHS, ischemic-reperfused tissue that had been treated with 10 M
NaHS 1 minute before reperfusion, and ischemic-reperfused tissue
that had been treated with 10 MNaHS 20 minutes before reperfu-
sion. The error bars show the standard deviation.ischemia will last several hours. Thus, to make treatment sith HS a translatable therapy, efficacy must be demon-
trated after several hours of ischemia. We are currently
nvestigating the maximal period of ischemia that can be
alvaged after ischemia and before reperfusion by treatment
ith NaHS.
Interestingly, the timing of HS delivery before reperfu-
ion was crucial in our in vivo model. When delivered only
minute before reperfusion, no protective effect was seen;
owever, when given 20 minutes before reperfusion, a
early complete protective effect was noted. The lack of
rotection seen with the later time point may be a result of
n incomplete distribution of the HS, or more likely indi-
ates that a finite interval of time is required to affect the
elevant protective pathways (eg, activation/phosphoryla-
ion of cell survival and antioxidant pathways).34
The lack of protection noted when HS was given 1
inute before reperfusion in this study contrasts with the
ndings of Elrod et al,27 who showed significant protection
n cardiac tissue when HS was given at the time of reperfu-
ig 5. Proposed multifactorial mechanism by which HS is cyto-
rotective against ischemia-reperfusion injury when delivered after
he onset of ischemia. HS present in the cell can be exogenous or
ndogenous (produced by cystathionine-	-synthase [CBS] and
ystathionine-	-lyase [CSE]) in nature and is thought to act as a
ree radical scavenger, an activator of the reperfusion injury salvage
inase pathway (RISK) pathway, and an opener of KATP channels,
ll of which promote cell survival via mitochondrial protection.
RK, Extracellular-regulated kinase; MPTP, 1-methyl-4-phenyl-
,2,3,6-tetrahydropyridine.ion. Other authors have shown efficacy at 5 and 10 min-
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mal time course of delivery, whether HS should be
delivered as a bolus or as a continual infusion, and what is
the optimal HS donor warrant further study.
CONCLUSIONS
This study is the first, to our knowledge, to concur-
rently evaluate both in vitro and in vivo the cytoprotective
effects of HS on skeletal muscle when delivered after an
ischemic event, and the results support our hypothesis that
pharmacologic postconditioning with HS significantly lim-
its IRI-induced damage. Although significant work remains
to be done regarding translation to larger animal models
and humans, we believe that these data provide an impor-
tant foundation to suggest that treatment with HS prior to
revascularization may prevent the morbidity (and possible
mortality) that can result from unanticipated ischemia in
skeletal muscle, and further work on this promising treat-
ment modality is warranted.
We thank Alice Harper for her assistance in the surgical
handling of the study animals.
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